Vinva Investment Management Ltd Boosts Holdings in IQVIA Holdings Inc. $IQV

Vinva Investment Management Ltd raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 173,471 shares of the medical research company’s stock after buying an additional 12,088 shares during the quarter. IQVIA comprises approximately 0.6% of Vinva Investment Management Ltd’s holdings, making the stock its 29th largest position. Vinva Investment Management Ltd owned about 0.10% of IQVIA worth $31,495,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its stake in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares in the last quarter. Westside Investment Management Inc. lifted its stake in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of IQVIA during the 3rd quarter valued at about $36,000. Root Financial Partners LLC purchased a new position in shares of IQVIA during the third quarter valued at about $43,000. Finally, Hantz Financial Services Inc. increased its holdings in shares of IQVIA by 92.0% in the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after purchasing an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $174.56 on Friday. The stock has a market cap of $29.62 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 1.68 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50 day moving average price of $207.22 and a 200-day moving average price of $207.47. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Citigroup dropped their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. UBS Group reduced their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Truist Financial lowered their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Morgan Stanley set a $240.00 price target on shares of IQVIA in a research report on Wednesday, February 11th. Finally, TD Cowen upped their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $231.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.